3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Renal Cell
6
Melanoma
4
Prostatic Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Kidney Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Upper Tract Urothelial Carcinoma
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
pembrolizumab
9
Nivolumab
5
tislelizumab
2
spartalizumab
2
belinostat
2
atezolizumab
2
Pemetrexed
2
Paclitaxel
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Docetaxel
2
Cisplatin
2
tocilizumab
1
sargramostim
1
obinutuzumab
1
niraparib
1
naptumomab estafenatox
1
milademetan
1
epacadostat
1
enzalutamide
1
durvalumab
1
cabozantinib
1
bosutinib
1
Sorafenib
1
Sirolimus
1
Quality of Life
1
Plicamycin
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Immunotherapy, Adoptive
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
Immunotherapy
×
Genitourinary
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled